Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Kilroy Conor reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 12,079 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 167,234 shares.
Plavsic Mark reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 15,890 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 181,397 shares.
Hopkins Janet Jill reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 20,401 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 232,284 shares.
Elazzouzi Amy reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 8,549 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 75,532 shares.
de los Pinos Elisabet reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 47,648 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 409,815 shares.
Aura Biosciences, Inc. received an updated Schedule 13G/A from a group of Frazier Life Sciences funds and related entities reporting passive ownership of its common stock.
Frazier Life Sciences Public Fund, L.P. directly holds 4,032,060 shares of Aura common stock, representing 6.3% of the class based on 63,503,269 shares outstanding as of November 10, 2025. Other affiliated Frazier funds directly hold additional stakes of 128,520 shares (0.2%), 342,210 shares (0.5%), and 597,210 shares (0.9%), with voting and investment power allocated through various Delaware limited partnerships and limited liability companies.
The filing notes that these ownership figures exclude prefunded warrants. The funds hold warrants to purchase 1,008,016, 32,130, 85,552, and 149,302 additional shares of common stock, each subject to a 9.99% beneficial ownership limitation, which prevents exercise if it would push the holder above that ownership threshold. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Aura Biosciences.
Aura Biosciences insider Amy Elazzouzi has filed a Form 144 indicating an intention to sell up to 1,581 shares of the company’s common stock through broker Morgan Stanley Smith Barney LLC on or about 01/20/2026. The filing lists an aggregate market value of $7,683.66 for this planned sale, with 63,503,269 shares of common stock outstanding and the stock listed on Nasdaq.
The securities to be sold were originally acquired as a restricted stock unit award granted on 01/19/2023 under Aura Biosciences’ 2021 Stock Option and Incentive Plan, in an amount of 2,844 shares. Over the past three months, the same seller has sold 896 shares of common stock for gross proceeds of $5,689.60. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about Aura Biosciences.
Aura Biosciences insider Elisabet de los Pinos has filed a Rule 144 notice to sell 16,928 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an indicated aggregate market value of $82,234.36 on Nasdaq. These shares relate to a restricted stock unit award of 30,469 shares granted on 01/19/2023 under the company’s 2021 Stock Option and Incentive Plan. The notice also discloses that 9,049 shares of common stock were sold in the past three months for $57,461.15. Aura Biosciences had 63,503,269 shares of common stock outstanding, providing scale for the planned sale.
Amy Elazzouzi, Senior Vice President, Finance of Aura Biosciences, Inc. (AURA), reported an insider transaction involving company common stock. On January 20, 2026, she sold 1,581 shares of common stock at $4.86 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, she beneficially owned 84,081 shares of Aura Biosciences common stock, held directly.
Aura Biosciences, Inc. director and President & Chief Executive Officer Elisabet de los Pinos reported an automatic sale of common stock to cover taxes on vesting restricted stock units. On January 20, 2026, she sold 16,928 shares of common stock at a weighted average price of $4.86 per share in multiple trades within a price range of $4.73 to $4.86. After this transaction, she beneficially owned 457,463 shares of Aura Biosciences common stock directly. An additional 127,763 shares were reported as indirectly owned through the Elisabet de los Pinos Revocable Trust, of which she is a trustee. The filing notes that the sales were solely to satisfy tax withholding obligations and were not made at her discretion.